Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIR-T CD33
- Development stage
- Preclinical
- Lead developer
- Angeles Therapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
SIR-T CD33 is an investigational cell therapy being developed by Angeles Therapeutics for the treatment of CD33-positive malignancies. The therapy utilizes the company's proprietary Synthetic Immune Receptor (SIR-T) platform, which involves engineering T cells with a modular receptor designed to mimic natural T-cell signaling pathways for improved activation and persistence. By targeting the transmembrane protein CD33, which is highly expressed on myeloid cells and leukemic blasts, SIR-T CD33 aims to selectively identify and eliminate cancerous cells in conditions such as acute myeloid leukemia (AML). The program is currently in the discovery stage of development.
- Other names
- SIR-T CD33
02
Targets
CD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on SIR-T CD33.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIR-T CD33.